Roche Holding Ltd · SIX:RO
Roche — Goldman Sachs 19th Annual European Medtech and Healthcare Services Conference 2022
19 slides from Roche's conference presentation, September 2022
Slide 1: Roche Diagnostics Division
Roche Diagnostics Division Thomas Schinecker CEO Roche Diagnostics
Slide 2: Burden of diseases on patients, societies and economies
Burden of diseases on patients, societies and economies Major disease areas cause enormous damage to patients and economies Causes of death globally (millions per year)1,2 Cardiovascular diseases 18 COVID-19 Infectious diseases 13 +4 20214 Cancer 10 >5tn CHF ECONOMIC IMPACT3 Injuries 4 Neurological
Slide 3: Roche Diagnostics' impact
Roche Diagnostics’ impact 70% of clinical decisions are informed by diagnostics No access Cervical cancer Tuberculosis HIV Disease burden 47% of population have little or no access to 342,000 women die every year 2 billion people infected >37 million people infected, diagnostics1 2/3 in Africa2 Hepa
Slide 4: Our contribution against COVID-19
Our contribution against COVID-19 Roche has enabled access to >1.7 billion tests to fight the COVID-19 pandemic 20+ solutions >1.7 billion COVID-19 Responsible pricing to >1’900 cobas® 6800/8800 tests enable access instruments placed1 Broad portfolio of COVID-19 Conducted with our products Costs sho
Slide 5: Infectious diseases across the globe
Infectious diseases across the globe Potential sources of the next pandemic Heartland Powassan virus Lyme Disease Drug-resistant malaria Diphtheria Enterovirus D68 Typhoid fever H3N2v influenza Cryptosporidiosis E.coli 0104:H4 Akmeta Virus MERS-CoV Anti Microbial resistant Rift Valley fever threats
Slide 6: Recent launches
Recent launches
Slide 7: Elecsys HCV DUO Immunoassay
Elecsys® HCV DUO Immunoassay1 Early diagnosis of hepatitis C virus (HCV) enables optimal treatment Diagnostic window period2 • 58m people being chronically infected globally (80% unaware3) and about 1.5m new infections per year 6-12 weeks • Hepatitis C leading cause for liver cancer and curative rel
Slide 8: cobas HPV self-sampling solution
cobas® HPV self-sampling solution Increasing screening adherence to potentially reach 1.7bn women globally cobas® HPV self- cobas® HPV test CINtec® Plus Cytology CINtec® Histology iThemba Life® 342,000 women sampling solution1 die per year of cervical cancer, ~90% in LMIC with majority unscreened 2
Slide 9: BenchMark ULTRA PLUS system
BenchMark ULTRA PLUS system1 Next instrument generation for tissue advanced staining Optimized workflow Flexible solutions • Shortened reagent validation • View, manage, complete and print • Reduced turnaround time system data remotely • Fewer manual interventions • Optimized protocols and slide sta
Slide 10: VENTANA DP 600 slide scanner
VENTANA DP 600 slide scanner Enhancing digital pathology with high volume slide scanner High volume scanning Leverages optical system of DP 200 240 slide capacity (40x more than DP200) consistent image quality Flexible workflows Continuous loading improve efficiency walk-away automation Slide scanne
Slide 11: Roche Digital LightCycler
Roche Digital LightCycler® Filling the gap between PCR and sequencing • Digital PCR system with IVD label & superior performance • Key differentiators: – Powerful analytical software & simpler workflow (no more emulsions) Analyzer Partition engine – Flexibility to tailor assays from high sensitivity
Slide 12: Upcoming launches
Upcoming launches
Slide 13: New system launches in US
New system launches in US Enabling comparable results in different size laboratories Throughput cobas® pure1 cobas® pro cobas® pro (high throughput) Increasing access Serum Work Area Family concept addressing solutions needs of all lab sizes Reducing cost Automation and tailored throughput help labo
Slide 14: cobas mass spectrometry
cobas® mass spectrometry First fully integrated IVD platform for mass spectrometry creates a new market segment Seamless integration Increased patient access into routine testing to standardized mass spec technology Only integrated platform 50% of non-users would start on the market if integrated pl
Slide 15: Breakthrough device designation for preeclampsia assays
Breakthrough device designation for preeclampsia assays Short-term prediction and appropriate management of preeclampsia Preeclampsia: 3-5% disease with unpredictable onset and clinical picture is not always clear1 of all pregnancies4 difficult assessment of severity prognosis1 timely decision criti
Slide 16: Breakthrough device designation for Alzheimer's IVD blood tests
Breakthrough device designation for Alzheimer’s IVD blood tests Enabling access to Alzheimer’s disease modifying therapies Non-AD patients1 Patients undergoing initial evaluation for • pTau 181 and ApoE4 have been selected based on clinical non-specific cognitive decline AD patients1 performance and
Slide 17: Key launches 2022
Key launches 2022 Area Product Description Market Status Automated immunohistochemistry/in situ hybridization (ISH) advanced staining platform with BenchMark ULTRA PLUS US & CE Pathology Lab enhanced software capabilities, workflow and testing efficiency DP600 High capacity pathology slide scanner f
Slide 18: Q&A
Q&A
Slide 19: Doing now what patients need next
Doing now what patients need next